Rocket Pharmaceuticals, Inc. Common Stock RCKT
$3.47
+3.89%
at last close
Analyst Consensus
- Consensus Rating
- Hold (4 Buy · 1 Hold · 2 Sell)
- Average Price Target
- $45.43
- Implied Upside
- +1209.2%
- Price Target Range
- $3.00 – $263.00
- Analysts (12 mo)
- 7
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| 2026-08-11 | WedbushYun Zhong |
Maintains | Outperform | $16 → $15 |
| 2026-05-11 | Chardan CapitalGeulah Livshits |
Maintains | Buy | $11 |
| 2026-03-30 | B of A SecuritiesJason Zemansky |
Maintains | Buy | $8 → $9 |
| 2026-03-27 | Chardan CapitalGeulah Livshits |
Maintains | Buy | $11 |
| 2026-03-02 | Goldman SachsRichard Law |
Maintains | Sell | $2 → $3 |
| 2026-02-27 | Cantor FitzgeraldJosh Schimmer |
Maintains | Overweight | $8 → $10 |
| 2025-11-18 | B of A SecuritiesJason Zemansky |
Maintains | Buy | $10 → $8 |
| 2025-11-18 | JP MorganTessa Romero |
Downgrades | Overweight → Underweight | $261 → $263 |
| 2025-10-14 | Chardan CapitalGeulah Livshits |
Maintains | Buy | $11 |
| 2025-10-03 | Leerink PartnersMani Foroohar |
Maintains | Market perform | $9 → $7 |
| 2025-08-20 | B of A SecuritiesJason Zemansky |
Upgrades | Neutral → Buy | $4 → $10 |
| 2025-08-20 | Chardan CapitalGeulah Livshits |
Maintains | Buy | $11 |
| 2025-08-11 | Chardan CapitalGeulah Livshits |
Maintains | Buy | $12 → $11 |
| 2025-08-08 | Cantor FitzgeraldJosh Schimmer |
Maintains | Overweight | $10 → $8 |
| 2025-07-25 | Canaccord GenuityWhitney Ijem |
Maintains | Buy | $11 → $10 |
| 2025-07-25 | B of A SecuritiesGreg Harrison |
Downgrades | Buy → Neutral | $9 → $4 |
| 2025-07-24 | Chardan CapitalGeulah Livshits |
Maintains | Buy | $17 → $12 |
| 2025-07-24 | NeedhamGil Blum |
Maintains | Hold | — |
| 2025-06-17 | UBSColin Bristow |
Maintains | Buy | $12 → $5 |
| 2025-06-03 | Canaccord GenuityWhitney Ijem |
Maintains | Buy | $34 → $11 |
| 2025-05-28 | B of A SecuritiesGreg Harrison |
Maintains | Buy | $32 → $9 |
| 2025-05-28 | BMO CapitalKostas Biliouris |
Maintains | Outperform | $30 → $8 |
| 2025-05-28 | ScotiabankGreg Harrison |
Maintains | Sector outperform | $51 → $19 |
| 2025-05-28 | Leerink PartnersMani Foroohar |
Downgrades | Outperform → Market perform | $37 → $8 |
| 2025-05-28 | Chardan CapitalGeulah Livshits |
Maintains | Buy | $46 → $17 |
| 2025-05-28 | JefferiesAndrew Tsai |
Downgrades | Buy → Hold | $29 → $3 |
| 2025-05-27 | NeedhamGil Blum |
Downgrades | Buy → Hold | $42 |
| 2025-05-16 | Cantor FitzgeraldJosh Schimmer |
Maintains | Overweight | $20 → $30 |
| 2025-05-16 | WedbushYun Zhong |
Reiterates | Outperform | $32 |
| 2025-05-16 | Chardan CapitalGeulah Livshits |
Maintains | Buy | $45 → $46 |
Ratings and price targets reflect each firm's most recent published action. Consensus combines the latest call from every covering firm over the past 12 months; price targets are typically 12-month horizons.
Key Stats
- Last Close
- $3.47
- Market Cap
- $380.92 million
- 52-Week Range
- $2.53 – $5.45
- Average Volume
- 1.72 million shs
Data is delayed and provided for informational purposes only. Not investment advice. See our disclaimer.